Oramed Pharmaceuticals Inc. (ORMP) Stock Price & How to Invest

Oramed Pharmaceuticals is a clinical-stage pharmaceutical company focused on the oral delivery of drugs that normally have to be injected. Its core intellectual property is the POD (Protein Oral Delivery) platform, and its best-known candidate is ORMD-0801, an oral insulin capsule aimed at diabetes, with additional early-stage work on an oral GLP-1 (ORMD-0901) and applications such as NASH. Because it has no approved product, Oramed generates little or no product revenue; it has historically funded itself through capital raises and has carried a substantial cash and investment position, including interests and notes tied to other companies, which sets it apart from many cash-strapped micro-cap biotechs.

The investment picture in 2026 is defined by setback and reinvention. A Phase 3 trial of ORMD-0801 in Type 2 diabetes failed to meet its primary endpoints, which reset the entire thesis and forced management to rethink the program. Oramed has since explored several structural moves: a planned joint venture (OraTech) with a Chinese partner that was later terminated when closing conditions were not met, and a subsequent strategic transaction involving Lifeward under which Oramed would transfer POD technology in exchange for an equity stake and potential future revenue. Management has also talked about running a revised oral insulin study targeting a narrower patient subset. The result is a company with meaningful cash but an uncertain clinical path, so the stock trades more on strategy announcements and balance-sheet value than on near-term product sales.

The dominant risk is clinical failure: Oramed is pre-revenue, its lead program already missed a Phase 3 endpoint, and there is no guarantee a revised trial succeeds or that regulators would approve the product. Financing and dilution are constant concerns for clinical-stage biotech, since new trials require capital that is often raised by issuing shares. The company's reliance on partnerships adds counterparty and execution risk, as shown when a planned joint venture was terminated after closing conditions went unmet. Part of Oramed's value sits in investments and notes tied to other companies, whose worth can be hard to assess and may be impaired. As a small-cap, the stock can be volatile and thinly followed, and it may move sharply on single announcements. None of this is investment advice.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Oramed Pharmaceuticals Inc.'s investor relations page or your broker.

• Stage: Clinical-stage: minimal or no recurring product revenue
• Lead asset: ORMD-0801 oral insulin (Phase 3 in Type 2 diabetes previously failed its primary endpoints)
• Balance sheet: Historically a sizable cash and investment position, including notes/interests tied to other companies; verify the latest figure in filings
• Profitability: Operating losses expected as R&D and trial costs continue; not consistently profitable
• Strategic status: Restructured around partnerships (a terminated JV, then a Lifeward technology transaction); path is qualitative and evolving
• Valuation lens: Trades more on cash/investment value and pipeline optionality than on earnings multiples; no meaningful P/E

Figures are approximate, qualitative, and tied to the asOf date; Oramed is a clinical-stage company whose situation changes with each filing and announcement, so verify live numbers, cash position, and trial status in the latest SEC filings and press releases before acting. Traditional earnings multiples are not meaningful for a pre-revenue biotech; value here reflects the odds of clinical success plus the worth of the balance sheet.

There are three common ways to get ORMP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ORMP sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ORMP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Oramed is a speculative clinical-stage biotech whose value hinges on reviving an oral insulin program that already failed a pivotal trial, offset by a sizable cash and investment position that gives it runway. It suits only investors comfortable with binary, pre-revenue drug-development risk.